U.S. Orders 1.5 Million Protein-based COVID-19 Vaccines

Novavax extends U.S. government partnership in 2023
Novavax vaccine
by Gerd Altmann
Gaithersburg (Precision Vaccinations)

Novavax, Inc. today announced a new agreement that would maintain the U.S. public's access to Novavax's protein-based COBID-19 vaccine.

And this contract will support the U.S. government's continued efforts to make Novavax's vaccine available for free to states, jurisdictions, federal pharmacy partners, and federally qualified health centers.

Confirmed on February 13, 2023, a modification to its existing agreement between Novavax and the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, includes the delivery of up to 1.5 million doses of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373).

And this new agreement will support the development of smaller dose vials, strain selection in line with U.S. Food and Drug Administration (FDA) recommendations, and a smooth transition to the commercial market when appropriate.

"This agreement acknowledges the need to offer the American people a diverse COVID-19 vaccine portfolio and underscores the importance of Novavax's partnership with the U.S. government to ensure continuous access to a protein-based option as part of public health measures," said John C. Jacobs, President and Chief Executive Officer, Novavax, in a related press release.

"We look forward to continuing our collaboration with the U.S. government on the development of our COVID-19 vaccine to meet the requirements of the FDA and our commercial customers for the upcoming 2023/2024 vaccination campaign."

The Novavax COVID-19 Vaccine, Adjuvanted, received emergency use authorization from the U.S. FDA for use to prevent COVID-19 in adults aged 18 and older and in adolescents aged 12 through 17 as a primary series and as a first booster dose at least six months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals aged 18 and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals aged 18 and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.

This contract is supported with previously allocated federal funds from HHS, the Administration for Strategic Preparedness and Response, and Biomedical Advanced Research and Development Authority, through the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense under Contract Number W15QKN-16-9-1002, Project Number MCDC2011-001.

The Novavax COVID-19 Vaccine, Adjuvanted vaccine, has not been approved or licensed by the U.S. FDA but has been authorized for emergency use by the FDA.

As of January 2023, over 94 million doses of the NVX-CoV2373 vaccine had been delivered globally in countries such as India (CovoVax™), Europe (Nuvaxovid™), and the U.K. Global information about the Novavax COVID-19 Vaccine is found on this weblink.

Article by
Donald Hackett